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ttp://dx.doi.org/10.1016/j.ajpath.2014.03.003X-linkedmyotubularmyopathy is a congenitalmyopathy causedby deﬁciencyofmyotubularin. Patients often
present with severe perinatal weakness, requiring mechanical ventilation to prevent death from respiratory
failure. We recently reported that an activin receptor type IIB inhibitor produced hypertrophy of type 2b
myoﬁbers and modest increases of strength and life span in the severely myopathicMtm1d4 mousemodel of
X-linkedmyotubularmyopathy.Wehavenowperformeda similar study in the less severely symptomaticMtm1
p.R69Cmouse in hopes of ﬁnding greater treatment efﬁcacy. Activin receptor type IIB inhibitor treatment of
Mtm1 p.R69C animals produced behavioral and histological evidence of hypertrophy in gastrocnemius
muscles but not in quadriceps or triceps. The ability of the muscles to respond to activin receptor type IIB
inhibitor treatment correlated with treatment-induced increases in satellite cell number and several muscle-
speciﬁc abnormalities of hypertrophic signaling. Treatment-responsiveMtm1 p.R69C gastrocnemiusmuscles
displayed lower levels of phosphorylated ribosomal protein S6 and higher levels of phosphorylated eukaryotic
elongation factor2 kinase thanwereobserved inMtm1p.R69Cquadricepsmuscleor inmuscles fromwild-type
littermates. Hypertrophy in the Mtm1 p.R69C gastrocnemius muscle was associated with increased levels of
phosphorylated ribosomal protein S6. Our ﬁndings indicate that muscle-, ﬁber type-, and mutation-speciﬁc
factors affect the response to hypertrophic therapies that will be important to assess in future therapeutic
trials. (Am J Pathol 2014, 184: 1831e1842; http://dx.doi.org/10.1016/j.ajpath.2014.03.003)Supported by NIH/National Institute of Arthritis and Musculoskeletal
and Skin Diseases grants R01 AR044345 (A.H.B.) and K08 AR059750-01
(M.W.L.), and Loan Repayment Program L40 AR057721-01 (M.W.L.),
Muscular Dystrophy Association grant MDA201302 (A.H.B.), the Where
There’s a Will There’s a Cure Foundation (A.H.B.), and the Joshua Frase
Foundation (A.H.B.).
Disclosures: J.L.L. is a former employee of Acceleron Pharma, Inc., S.P.
is a current employee of Acceleron Pharma, Inc., and both have equity in
Acceleron Pharma, Inc., which manufactures the soluble activin type IIB
receptor (ActRIIB)-mFC used in this study.X-linked myotubular myopathy (XLMTM) is a severe form
of congenital myopathy with an estimated incidence of
1:50,000 male births that most often presents with severe
perinatal weakness and respiratory failure.1,2 Many patients
with XLMTM die within the ﬁrst year of life despite the use
of mechanical ventilation, and no treatments approved by
the Food and Drug Administration are available. XLMTM
is caused by mutations in the gene that encodes myotubularin
(MTM1), which is a phosphoinositide phosphatase thought tostigative Pathology.
.
Lawlor et albe involved in endosomal trafﬁcking, cytoskeletal organi-
zation, apoptosis, and/or maintenance of the sarcoplasmic
reticulum/T-tubular system within myoﬁbers.3e8 Muscle
biopsies from patients with XLMTM display excessively
small ﬁbers with increased numbers of ﬁbers that contain
central nuclei and central aggregation of organelles.9
Although the number of centrally nucleated ﬁbers bears lit-
tle relationship to a patient’s prognosis, there is a clear cor-
relation between the degree of ﬁber smallness at birth and the
severity of the patients’ disease.10 Two murine models of
myotubularin deﬁciency are used, the severely symptomatic
Mtm1d4 (also referred to as Mtm1 knockout in prior
studies3,11,12) and the moderately symptomaticMtm1 p.R69C
mice,13 both of which display weakness and myoﬁber
smallness and similar pathology to that seen in XLMTM.
Because of the relationship between myoﬁber size and
symptomatic severity in patients with XLMTM and in
Mtm1d4 mice, we had previously hypothesized that cor-
rection of myoﬁber smallness in myotubularin deﬁciency
would greatly improve strength. Inhibitors of myostatin or
nonfunctional decoys of its receptor, the activin type IIB
receptor (ActRIIB), can be used to inhibit this negative
regulator of myoﬁber size, leading to myoﬁber hypertrophy.
Myostatin binds to (and signals through) the ActRIIB to
activate the transforming growth factor-b pathway, which
prevents progression through the cell cycle and down-
regulates several key processes related to myoﬁber hyper-
trophy.14,15 We recently reported a trial of ActRIIB-mFC in
Mtm1d4 mice, which produced 17% extension of life span,
with transient increases in weight, forelimb grip strength,
myoﬁber size, and myoﬁber hypertrophy restricted to type
2b myoﬁbers in Mtm1d4 animals.12 Interestingly, ActRIIB-
mFc produces hypertrophy in all muscle ﬁber types in wild-
type (WT) mice,12,16 which suggests that myotubularin
deﬁciency interferes with the activation of hypertrophic
pathways in oxidative ﬁbers.
We hypothesized that the transience of the therapeutic
effects observed in treated Mtm1d4 mice may have been
related to the severity of the disease, so we have now
repeated this study in the less severely affected Mtm1
p.R69C mouse.13 Surprisingly, treatment of Mtm1 p.R69C
mice did not produce signiﬁcant increases in animal weight
or grip strength, and treatment-induced myoﬁber hypertro-
phy was only observed in the Mtm1 p.R69C gastrocnemius
muscles. The ability of these muscles to respond to
ActRIIB-mFC treatment correlated with treatment-induced
increases in satellite cell number and several muscle-
speciﬁc abnormalities of hypertrophic signaling. The main
difference between treatment-responsive (gastrocnemius)
and treatment-resistant (quadriceps) muscles in Mtm1
p.R69C mice was related to low levels of phosphorylated
ribosomal protein 6 (p-rpS6) and high levels of eukaryotic
elongation factor 2 kinase (eEF2K) in the treatment-
responsive gastrocnemius muscle that were not observed
in other Mtm1 p.R69C muscles or in WT mice. rpS6 and
eEF2K are terminal signaling molecules of the insulinlike1832growth factor-1/Akt and extracellular signal-related kinase
(ERK) pathways that are involved in the ﬁne-tuning of
global protein synthesis, with a role in the determination of
cell size that remains unclear (reviewed in Meyuhas17). Our
ﬁndings indicate that the response to hypertrophic agents
does not always correlate with activities of known hyper-
trophic pathways, such as the Akt pathway, but unexpect-
edly varies both by muscle type and ﬁber type and in
XLMTM is affected by the nature of the Mtm1 mutation.
These results highlight that there is much we still do not
understand about the control of muscle size and emphasize
the importance of evaluating multiple muscle and ﬁber types
in future trials of hypertrophic therapies.
Materials and Methods
Live Animal Studies
All studies were performed with approval from the Institu-
tional Animal Care and Use Committee at Boston Children’s
Hospital. Genotyping of MTM1/C57BL6 (Mtm1d4) and
Mtm1 p.R69C/C57BL6 (Mtm1 p.R69C) mice was performed
as previously described.12,13,18 Male WT and Mtm1 p.R69C
mice were given intraperitoneal injections twice per week
with a soluble ActRIIB-mFC (alias RAP-031; Acceleron
Pharma, Cambridge, MA) at a dose of 20 mg/kg or an
equivalent volume of Tris-buffered saline (the vehicle used
with ActRIIB-mFc), as previously described12 from 14 days
until 6 months of life (MOL). Animals were sacriﬁced at 6
MOL because of a plateau in observable therapeutic effects.
Animals were weighed twice per week during the treatment
period. Forelimb grip strength was measured weekly with the
use of a Chatillon grip force meter (Columbus Instruments,
Columbus, OH) by placing the animal on a horizontal grid
and allowing it to pull away from the experimenter by using
only its fore limbs. The maximum of three independent
measurements, with a 1-minute recovery period between
measurements, was used for subsequent statistical analysis.
To evaluate antigravity hanging performance, animals were
tested weekly by placing the animal on a rigid mesh surface,
inverting the surface at a height of approximately 40 cm
above their cage, and recording the amount of time necessary
for the animal to fall back into the cage. Animals that did not
fall within 60 seconds were lowered back into their cages.
The maximum of three independent measurements, with a
1-minute recovery period between measurements, was used
for subsequent statistical analysis.
Pathological Evaluation and Tissue Collection
Animals were euthanized with carbon dioxide followed by
cervical dislocation, per the regulations of the Institutional
Animal Care and Use Committee at Children’s Hospital
Boston. Animals were photographed intact and after removal
of the skin from the torso and limbs. The quadriceps, gastroc-
nemius, triceps, soleus, extensor digitorum longus, andajp.amjpathol.org - The American Journal of Pathology
ActRIIB Inhibition in Mtm1 p.R69C Micediaphragm muscles were removed, weighed, and frozen in
liquid nitrogen-cooled isopentane.
Histological Evaluation
Myoﬁber Analysis
Cross sections (8 mm) of isopentane-frozen quadriceps,
gastrocnemius, or triceps muscles were taken midway down
the length of the muscle and stained with H&E for evaluation
with the use of an Olympus BX53 microscope with an
Olympus DP72 camera and cellSens Standard software
version 1.5 (Olympus, Center Valley, PA). Fiber size was
determined through measurements of MinFeret diameter, as
we have previously used,12 because this measurement offers
a myoﬁber size measurement that is relatively independent of
ﬁber orientation.19 Overall ﬁber size and the number of
internally nucleated ﬁbers were manually measured with
micrographs of two 100 magniﬁcation ﬁelds (using a 10
objective lens) of H&E-stained slides (range, 259 to 1113
ﬁbers; nZ 4 to 5 animals quantiﬁed per treatment group). To
evaluate ﬁber type-speciﬁc responses, 8 mm frozen transverse
sections of quadriceps muscle were double-stained with
rabbit anti-dystrophin antibodies (ab15277; Abcam, Cam-
bridge, MA) and mouse monoclonal antibodies against
myosin heavy chain type 1 (Skeletal, Slow, cloneNOQ7.5.4D;
Sigma-Aldrich, St. Louis, MO), type 2a (clone SC-71;
Developmental Studies Hybridoma Bank, Iowa City, IA),
or type 2b (clone BF-F3; Developmental Studies Hybridoma
Bank). Secondary antibodies included ﬂuorescein
isothiocyanate-conjugated anti-mouse IgG (Sigma-Aldrich) or
IgM (dilution 1:100; Sigma-Aldrich) and Alexa Fluor-
conjugated anti-rabbit IgG (Molecular Probes, Carlsbad,
CA). Because of variation in the number and type of oxidative
ﬁbers (type 1 and 2a ﬁbers) in mouse muscle, quantiﬁcation
was performed by evaluating the type 2b myosin-positive
(glycolytic) and type 2b myosin-negative (oxidative) pop-
ulations on a whole-slide scan of one quadriceps and one
gastrocnemius muscle from four vehicle-treated WT mice,
four ActRIIB-mFcetreated WT mice, six vehicle-treated
Mtm1 p.R69C mice, and six ActRIIB-mFcetreated Mtm1
p.R69C mice. MinFeret diameter was evaluated by using a
novel automated technique developed by Dr. Lin Yang that
correlated extremely well with our manual measurements.12
The automated image quantiﬁcation algorithm began with
ridge detection to enhance the muscle ﬁber boundaries, fol-
lowed by robust seed detection that was based on concave area
identiﬁcation to ﬁnd initial seeds for muscle ﬁbers. The ﬁnal
muscle ﬁber boundaries were automatically delineated with a
gradient vector ﬂow deformable model. After each ﬁber was
automatically and accurately delineated, the MinFeret diam-
eter was calculated by ﬁnding the shortest axis along the
segmented contour of each muscle ﬁber. The number of
muscle ﬁbers was determined with scanned slides that had
been stained with anti-dystrophin antibodies. A software
analysis algorithm was developed with Visiomorph software
version 3.4.3.0 (Visiopharm, Medicon Valley, Denmark) toThe American Journal of Pathology - ajp.amjpathol.orgallow the distinction between black pixels inside myoﬁbers
from the white/gray pixels (in grayscale) in areas of dystrophin
staining. Bayesian classiﬁcation was used to segment the
image, and postprocessing steps were applied related to shape
and area to disregard counted areas that did not correspond to
myoﬁbers. Fiber count analysis was performed on muscles
from four to six animals per treatment group for both the
quadriceps and gastrocnemius muscles.
Satellite Cell Quantiﬁcation
The quantiﬁcation of satellite cells was performed with
immunoperoxidase staining for Pax7 (Developmental Studies
Hybridoma Bank) and biotin-SPeconjugated donkey anti-
mouse IgG Fab fragment, as previously described.8 Images
were quantiﬁed by counting the number of Pax7þ cells
within a ﬁeld and dividing by the total number of ﬁbers
(range, 1117 to 3631 ﬁbers; n Z 3 animals quantiﬁed per
treatment group).
Hypertrophic Pathway Studies
Muscle tissues from the quadriceps, gastrocnemius, triceps,
and elsewhere in the fore and hind limbs from WT and
Mtm1 p.R69C mice at 6 MOL or WT and Mtm1d4 mice at
6 weeks of life (WOL) were frozen at the time of necropsy
and stored at 80C until analysis. Frozen muscles were
crushed in liquid nitrogen and homogenized with lysing
buffer (Cell Signaling Technology, Danvers, MA) that
contained protease inhibitor (Roche, Basel, Switzerland)
and phosphatase inhibitor (Roche). Western blot procedures
were performed as previously described.20 Transferred
proteins were probed with antibodies against a variety of
antigens. Antibodies that recognize the following antigens
were all obtained from Cell Signaling Technologies: Akt
(4691), phospho-Akt (Thr308; 2965), phospho-Akt (Ser473;
4060), S6 ribosomal protein (2217), phospho-S6 ribosomal
protein (Ser240/244; 5364), ERK (4695), phospho-ERK
(ERK 1/2, Thr202/204; 4370), p70-S6 kinase (S6K; 2708),
phosphoep70-S6K (Thr421/Ser424; 9204), p90-ribosomal
S6 kinase (RSK)1/2/3 (9355), phosphoep90-RSK (Ser380;
9335), phosphoe4E-BP1(Thr37/46; 2855), and phospho-
eEF2K (Ser366; 3691). Other antibodies used for Western
blot studies recognize myostatin (MAB788; R&D Systems,
Minneapolis, MN), ActRIIB (ab76940; Abcam), and glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH; G8795;
Sigma-Aldrich) and were visualized with chemiluminescent
horseradish peroxidase antibody detection reagent (Denville
Scientiﬁc, Metuchen, NJ). Adequacy of transfer was deter-
mined by Ponceau S staining. Quantiﬁcation of protein levels
normalized to GAPDH was performed with ImageJ software
version 1.45s (NIH, Bethesda, MD). Samples from four an-
imals per treatment group were used for analysis. Two
additional Mtm1 p.R69C/vehicle and Mtm1 p.R69C/
ActRIIB-mFc animals were added to the quantitative evalu-
ation of total and p-rpS6 (based on results from replicate gels)
to further establish the degree of interanimal variability.1833
Lawlor et alStatistical Analysis
Statistical evaluation was performed with Prism software
version 4 software (GraphPad, Inc., San Diego, CA) or by
statisticians at the Quantitative Health Sciences Section at
the Medical College of Wisconsin. For statistical analysis of
animal weight, forelimb grip strength, and antigravity
hanging performance, analyses of variance were performed
with Bonferroni posttests. For muscle weight and average
myoﬁber diameter measurements, one-way analyses of
variance with Bonferroni posttests were performed. For
statistical analysis of Western blot data, t-tests were used to
compare protein expression between different genotypes or
treatments, and paired t-tests were used to compare protein
expression between the gastrocnemius and quadriceps
muscles of the same genotype and treatment group.
Results
Weight Studies
In animals that received vehicle injections, Mtm1 p.R69C
animals were distinguishable from age-matched WT ani-
mals on the basis of weight at 7 WOL (P < 0.05)
(Figure 1A). These differences increased as the animals
became older because of continued weight gain in WT an-
imals, in contrast to the relative weight plateau seen after 7
WOL in Mtm1 p.R69C animals. ActRIIB-mFcetreated WT
mice showed signiﬁcant weight gains in comparison with
vehicle-treated animals at 6 WOL (P < 0.05) that continued
to increase with age. ActRIIB-mFCetreated Mtm1d4 ani-
mals displayed a consistent slight increase (averaging 1 to
2 g) in weight that did not reach statistical signiﬁcance and
did not show the continued increases observed in WT mice.
Antigravity Hanging Performance
WT mice displayed the ability to hang for up to 60 seconds
(the maximum period tested) after 3 WOL (Figure 1B).
Treatment of WT mice with ActRIIB-mFC did not affect
antigravity hanging performance. Vehicle-treated Mtm1
p.R69C animals exhibited signiﬁcantly impaired hangingFigure 1 Behavioral ﬁndings in vehicle- and ActRIIB-mFCetreated mice. A: B
hanging performance of VEH- and ActRIIB-treated mice. WT and R69C mice were si
ActRIIB-treated mice. No signiﬁcant differences were seen for R69C/VEH compar
animals for each treatment group. *P < 0.05 (A and C). ActRIIB, ActRIIB-mFC;
1834performance at 4 WOL (P< 0.05), which, although variable,
did not degenerate into the complete inability for antigravity
hanging that we observed inMtm1d4 mice.12 Treatment with
ActRIIB-mFC did not signiﬁcantly improve the antigravity
hanging performance of Mtm1 p.R69C mice.
Forelimb Grip Strength
Forelimb grip strength measurements were consistently
lower inMtm1 p.R69C mice than in WT mice after 12 WOL
(P < 0.05) (Figure 1C). ActRIIB-mFCetreated WT animals
also showed an increase in grip strength as the treatment
period progressed (P < 0.01); however, treatment with
ActRIIB-mFC did not measurably improve forelimb grip
strength performance of Mtm1 p.R69C mice.
Gross Evaluation
Mtm1 p.R69C mice can be easily distinguished from WT
mice by gross and histological examination.13 Mtm1
p.R69C mice are smaller than age-matched WT mice and
have proportionately smaller muscles (data not shown). At 6
MOL (ie, after 5.5 months of treatment), ActRIIB-mFC
treatment of WT animals produced signiﬁcant increases in
mass of the quadriceps, triceps, and gastrocnemius muscles
(P < 0.05), but only the gastrocnemius muscle of treated
Mtm1 p.R69C mice showed signiﬁcant treatment-induced
increases in mass (P < 0.05) (Figure 2A).
Histological Examination
Myoﬁber Analysis
As previously described,13 quadriceps muscle ﬁbers of
vehicle-treated Mtm1 p.R69C mice are smaller than those
found in age-matched WT mice, with mean ﬁber diameters of
24  0.53 and 51  1.27 mm, respectively, by 6 MOL
(shown as means  SEM; P < 0.05) (Figure 2). Although
central nucleation is not a major pathological feature in this
animal model, muscles of Mtm1 p.R69C mice showed
increased numbers of centrally nucleated ﬁbers in comparison
with WT muscles (WT/vehicle quadricepsZ 1.43%  0.8%,
R69C/vehicle quadriceps Z 5.3%  1.0%, WT/vehicleody weight of VEH- and ActRIIB-treated WT and R69C mice. B: Antigravity
gniﬁcantly different after 3 weeks of age. C: Forelimb grip force of VEH- and
ed with R69C/ActRIIB animals. Data are expressed as means  SEM of (n)
R69C, Mtm1 p.R69C; VEH, vehicle.
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ActRIIB Inhibition in Mtm1 p.R69C Micegastrocnemius Z 0.8%  0.3%, and R69C/vehicle
gastrocnemius Z 4.9%  1.4% internally nucleated ﬁbers;
P < 0.05), and the number of internally nucleated ﬁbers did
not signiﬁcantly increase or decrease after ActRIIB-mFcFigure 2 Histological evaluationofVEH-andActRIIB-mFCetreatedmice.A:
Weights of individual muscles in treated and untreated animals at 6 MOL. B:
Myoﬁber size of VEH- and ActRIIB-mFCetreated WT and R69C mice, as measured
by manual MinFeret diameter measurements of H&E-stained slides. C: H&E-
stained transverse sections from the quadriceps and gastrocnemius muscles of
VEH- and ActRIIB-mFCetreated WT and Mtm1d4 mice. D and E: Automatic
morphometric measurements of MinFeret diameter were made for ﬁber type, and
frequency histograms for the quadriceps (D) and gastrocnemius (E) muscles are
shown. Measurements from VEH-treated mice are shown with black bars and
measurements from ActRIIB-mFcetreated mice are shown with white bars.
Glycolytic ﬁbers represent the population of ﬁbers that is positive for type 2b
myosin, and oxidative ﬁbers represent the population of ﬁbers that was negative
for type 2b myosin. Data are expressed as means  SEM. Quantiﬁcations were
performed on whole-slide scans of the entire muscle on four animals per treat-
mentgroup. *P< 0.05. ScalebarZ50mm(C). R69C,Mtm1p.R69C; VEH, vehicle.
The American Journal of Pathology - ajp.amjpathol.orgtreatment. Treatment of WT animals with ActRIIB-mFC
increased myoﬁber size by 6 MOL, as evidenced by a 5-
mm (10%) increase in mean ﬁber diameter and an increased
percentage of large ﬁbers within the gastrocnemius and
quadriceps muscles (Figure 2). Immunostaining for oxidative
(type 1 or 2a) or glycolytic (type 2b) myosin subtypes within
these muscles indicated that all types of WT muscle ﬁbers
experienced hypertrophy in response to ActRIIB-mFC treat-
ment, as evidenced by a rightward shift in histograms of ﬁber
size (Figure 2, D and E). In contrast, the gastrocnemius, but
not quadriceps, muscles from ActRIIB-mFCetreated Mtm1
p.R69C animals showed marked hypertrophy in only a sub-
population of muscle ﬁbers compared with their vehicle-
treated counterparts, with a 10-mm (32%) increase in mean
ﬁber diameter in the gastrocnemius muscle (P < 0.05) and no
signiﬁcant increase in the quadriceps muscle. Hypertrophy in
treated Mtm1 p.R69C mice was noted only in the glycolytic
type 2b ﬁbers, similar to what was seen in our prior study of
Mtm1d4 mice (Figure 2, D and E).12 The proportion of type
1, 2a, and 2b ﬁbers was highly variable between individual
animals, but no signiﬁcant differences were noted for ge-
notype or treatment group (data not shown). In addition,
counts of myoﬁber number within the gastrocnemius
muscle indicated no signiﬁcant difference between WT and
Mtm1 p.R69C mice (WT/vehicle gastrocnemius Z
5898  222 ﬁbers, R69C/vehicle gastrocnemius Z
5743  425 ﬁbers; shown as means  SEM; PZ 0.56), or
between vehicle- and ActRIIB-mFCetreated mice of either
genetic background (WT/ActRIIB-mFc gastrocnemius Z
6432  496 ﬁbers, R69C/ActRIIB-mFc gastrocnemius Z
6391  543 ﬁbers). Similar results were observed on ﬁber
counts in the quadriceps muscle (WT/vehicle quadricepsZ
4821  412 ﬁbers, R69C/vehicle quadricepsZ 6290  249
ﬁbers, WT/ActRIIB-mFc quadriceps Z 5294  299 ﬁbers,
and R69C/ActRIIB-mFc quadriceps Z 6976  557 ﬁbers),
where, despite a baseline difference between WT/vehicle and
R69C/vehicle specimens (possibly because of differences in
sampling; P < 0.05), no change was found in ﬁber number
after treatment of WT (PZ 0.37) or R69C (PZ 0.30) mice.
These results are consistent with a muscle type-restricted
histological improvement of Mtm1 p.R69C mice after
ActRIIB-mFC treatment, which accounts for the observed
increases in gastrocnemius weight at the same stage.
Satellite Cell Quantiﬁcation
The restriction of hypertrophy to certain muscles in Mtm1
p.R69C mice suggests factors affecting treatment efﬁcacy
may be differentially distributed among certain muscles.
Because we have recently described abnormalities of satel-
lite cell number in the Mtm1d4 model of myotubularin
deﬁciency,8 we evaluated satellite cell number in the
gastrocnemius and quadriceps muscles of vehicle- and
ActRIIB-mFcetreated Mtm1 p.R69C mice with the use of
immunoperoxidase staining for Pax7 to determine whether
treatment responsiveness in these muscles correlated with
satellite cell behavior. Similar to what was seen in Mtm1d41835
Figure 3 Pax7þ satellite cell quantiﬁcation in VEH- and ActRIIB-
treated mice. A: Immunostaining results for Pax7 in the gastrocnemius
muscle of VEH- and ActRIIB-treated WT and R69C mice at 6 MOL. B:
Quantiﬁcation of Pax7þ cells in the quadriceps and gastrocnemius muscles
of treated and untreated mice, expressed as the number of satellite cells
observed divided by the number of ﬁbers in the evaluated images. Data are
expressed as means  SEM. *P < 0.05. Scale bar Z 50 mm. ActRIIB,
ActRIIB-mFC; R69C, Mtm1 p.R69C; VEH, vehicle.
Lawlor et almice,12 the gastrocnemius and quadriceps muscles of vehicle-
treatedMtm1 p.R69Cmice both displayed severe depletion of
satellite cells at 6 MOL (<2% of ﬁbers with one or more
associated satellite cells inMtm1 p.R69Cmice versus>5%of
ﬁbers with associated satellite cells in WT mice in both
muscles; P < 0.05) (Figure 3). However, ActRIIB-mFc
treatment differentially increased satellite cell numbers in
Mtm1 p.R69C gastrocnemius versus quadriceps muscles. In
WT muscles (both gastrocnemius and quadriceps) and in the
gastrocnemius muscles ofMtm1 p.R69Cmice, ActRIIB-mFc
treatment was associated with a higher number of satellite
cells per ﬁber (77% increase in satellite cells/ﬁber in WT/
ActRIIB quadriceps, 87% increase in satellite cells/ﬁber in
WT/ActRIIB gastrocnemius, and 52% increase in satellite
cells/ﬁber in R69C/ActRIIB gastrocnemius; P < 0.05)
(Figure 3). By contrast, no such increase was observed in the
quadriceps muscles of ActRIIB-mFcetreated Mtm1 p.R69C
mice (18% decrease in satellite cells/ﬁber in R69C/ActRIIB
quadriceps) (Figure 3).Figure 4 Expression of myostatin and activin receptor type IIB in VEH-
and ActRIIB-treated mice. A: Western blot analysis shows the relative
expression of myostatin and the activin type IIB receptor in the quadriceps
and gastrocnemius muscles of VEH- and ActRIIB-treated WT and R69C mice
at 6 MOL. GAPDH staining is used as a basis for loading and quantiﬁcation
studies. The numbers under each set of two lanes refer to individual mice
from the study. B: Quantiﬁcation of myostatin and activin type IIB receptor
expression in the quadriceps and gastrocnemius muscles of VEH- and
ActRIIB-treated WT and R69C mice. Expression is normalized to the GAPDH
expression for each lane. These values were obtained from gels in which the
WT and R69C samples were run in parallel on the same gels and immuno-
blotted on the same membranes. Data are expressed as means  SEM.
*P < 0.05. ActRIIB, ActRIIB-mFC; G, gastrocnemius; Q, quadriceps; R69C,
Mtm1 p.R69C; VEH, vehicle.Hypertrophic Pathway Studies
Differential activation of hypertrophic pathways within
different muscles is a possible explanation for the muscle-
speciﬁc treatment efﬁcacy observed in Mtm1 p.R69C mice.
Endogenous amounts of the activin type 2B receptor were
variable but equivalent in the gastrocnemius and quadriceps
muscles of Mtm1 p.R69C mice (Figure 4). Treatment with
ActRIIB-mFc variably increased activin type 2B receptor
levels in allmuscles, butwewere unable to determinewhether
this was because of actual up-regulation of the receptor or
cross-reactivity with injected ActRIIB-mFc (Figure 4).1836Endogenous myostatin levels tended to be inherently
lower in both Mtm1 p.R69C muscles than in WT muscles,
but they were lowest in Mtm1 p.R69C quadriceps. ActRIIB-
mFc treatment tended to reduce myostatin levels further in
all muscles, but none of these effects was statistically sig-
niﬁcant. Because myostatin inhibits hypertrophic signaling
(Figure 5), the fact that myostatin levels showed a trend
higher in Mtm1 p.R69C gastrocnemius versus quadriceps
muscles with and without treatment led us to look at other
signaling pathways to account for the differential sensitivity
of gastrocnemius muscle to ActRIIB-mFc.
As noted above, treatment-related hypertrophy was
restricted to glycolytic (type 2b) myoﬁbers in Mtm1 p.R69C
mice, which is the same pattern that we previously encoun-
tered after treatment of Mtm1d4 mice with ActRIIB-mFc.12
Because the insulinlike growth factor-1/Akt pathway is
responsible for hypertrophy of type 2b myoﬁbers, and pre-
vious work has established a link between the myostatin
pathway and insulinlike growth factor-1/Akt pathway
(reviewed in Han et al21), we focused on several elements of
the Akt pathway to evaluate whether baseline levels or signalajp.amjpathol.org - The American Journal of Pathology
Figure 5 Simpliﬁed signaling pathway for muscle hypertrophy. Elements
of the Akt and ERK pathways evaluated in the present study are shown.
ActRIIB Inhibition in Mtm1 p.R69C Miceactivation behaved in a muscle-speciﬁc fashion (Figures 5
and 6). Given the observed pattern of treatment efﬁcacy,
we hypothesized that the most relevant signaling molecule(s)
would show differential expression or phosphorylation when
comparing the gastrocnemius and quadriceps muscles from
vehicle- and ActRIIB-treated Mtm1 p.R69C mice (Figure 6,
A and B). Levels of total and p-Akt kinase were similar in the
quadriceps and gastrocnemius muscles of these mice, but two
proteins associated with the terminal steps of the Akt
pathway, rpS6 and eEF2K, did show signiﬁcantly different
levels of phosphorylation. Speciﬁcally, rpS6 showed low
levels of phosphorylation in vehicle-treated Mtm1 p.R69C
gastrocnemius muscles and considerably higher levels of
phosphorylation inMtm1 p.R69C quadriceps muscles in ﬁve
of the six animals tested (Figure 6), whereas the levels of p-
eEF2K were consistently higher in gastrocnemius muscles.
High levels of p-rpS6 and p-eEF2K were also seen in age-
matched WT muscles (both gastrocnemius and quadriceps)
(Figure 6). Treatment of Mtm1 p.R69C mice showed a trend
toward increased rpS6 phosphorylation in the gastrocnemius
muscle (PZ 0.06), but produced no change in the already high
level of p-rpS6 in the quadriceps muscle (Figure 6). Total levels
of P70/S6K, the upstream kinase for both rpS6 and EF2K, were
higher in ActRIIB-treated gastrocnemius muscles, and p-P70/
S6K showed a trend toward increased levels in ActRIIB-treated
gastrocnemius muscles, as well. Taken together, these results
suggest a differential effect at the level of P70/S6K localization
or relative substrate utilization. With respect to eEF2K, a higher
level of p-eEF2K was seen in theMtm1 p.R69C gastrocnemius
muscles than in the quadriceps muscles (P < 0.05) (Figure 6),
but this did not change with ActRIIB-mFc treatment.
We similarly evaluated Akt signaling intermediates in
gastrocnemius and quadriceps muscles from the ActRIIB-
responsive Mtm1d4 mice (Supplemental Figure S1). FrozenThe American Journal of Pathology - ajp.amjpathol.orgmuscles fromMtm1d4 andWTmice at 6WOL (the strain and
time point used in our prior published trial) showed variable
p-rpS6 levels within and between animals. Although the same
trends were apparent in the muscles from the two different
mutant strains, the muscle type-speciﬁc differences in p-rpS6
and p-eEF2K levels inMtm1d4 muscles were not statistically
signiﬁcant (Supplemental Figure S1). In side-by-side com-
parisons (not shown), the amount of p-rpS6 in WT and
Mtm1d4 animals was considerably higher than that seen in the
Mtm1 p.R69C gastrocnemius muscle, suggesting that the low
levels of p-rpS6 in this muscle represent the true signaling
abnormality.
Because rpS6 can alternatively be phosphorylated through
the ERK pathway via RSK/P90, the levels of total and p-ERK
and RSK/P90 were also evaluated (Figure 7). No signiﬁcant
differences were found in the baseline levels of upstream
kinases of the Akt or ERK pathways which would explain
the low levels of p-rpS6 observed in the Mtm1 p.R69C
gastrocnemius muscle (Figures 5, 6, and 7).
Vehicle-treated WT animals displayed no signiﬁcant
differences in hypertrophic pathway activation compared
with the gastrocnemius and quadriceps muscles from the
same animal (Figures 6 and 7). Treatment of WT mice with
ActRIIB-mFc produced a signiﬁcant increase in the total
levels of Akt and P70/S6K, but no signiﬁcant differences in
the phosphorylation of these proteins.
Discussion
Because of the relationship between myoﬁber size and symp-
tomatic severity inpatientswithXLMTMand inmyotubularin-
deﬁcient mice, we had previously hypothesized that correction
of myoﬁber smallness in myotubularin deﬁciency would
greatly improve strength. Our initial study that used ActRIIB-
mFc in the severely symptomatic Mtm1d4 mouse model of
XLMTM suggested that inhibition of myostatin and ActRIIB
by using this drug produced generalized increases in animal
mass, muscle mass, and type 2b myoﬁber size with slight in-
creases in forelimb grip strength and survival.12 In the present
study, we performed a similar trial on the less severely symp-
tomatic Mtm1 p.R69C mouse model13 to determine the po-
tential of this treatment strategy in less severely symptomatic
patients with XLMTM. Surprisingly, we report here that
ActRIIB-mFc is less effective as a treatment forMtm1 p.R69C
mice than for Mtm1d4 mice and that treatment-induced hy-
pertrophy was restricted to speciﬁc muscles within Mtm1
p.R69C animals. After evaluating several factors thatmay vary
between individualmuscles, we have found that the inability to
respond to ActRIIB-mFc therapy was associated with reduced
numbers of satellite cells in the muscle. In addition, we found
abnormalities of hypertrophic signaling in the treatment-
responsive Mtm1 p.R69C gastrocnemius muscle that were
not present in the treatment-resistantMtm1 p.R69C quadriceps
muscle or in WT muscles, including low levels of p-rpS6 and
high levels of p-eEF2k. Although the relationship between
each of these factors and treatment efﬁcacy remains unclear,1837
Figure 6 Akt pathway activation in VEH- andActRIIB-treatedmice.A:Western blot analysis shows the relative expression of Akt, p-Akt (at Ser473 and Thr308),
total P70/S6K, p-P70/S6K (at Thr421/Ser424), rpS6, p-rpS6 (at Ser240/244), p-4EBP1 (at Thr37/46), andp-eEF2K (at Ser366) in the quadriceps andgastrocnemius
muscles of VEH- and ActRIIB-treated WT and R69Cmice at 6 MOL. GAPDH staining is used as a basis for loading and quantiﬁcation studies. The numbers under each
set of two lanes refer to individual mice from the study. B: Quantiﬁcation of the Western blot analysis results shown in A. Expression is normalized to the GAPDH
expression for each lane. These values were obtained from gels in which the WT and R69C samples were run in parallel on the same gels and immunoblotted on the
same membranes. Data are expressed as means  SEM. *P < 0.05. ActRIIB, ActRIIB-mFC; G, gastrocnemius; Q, quadriceps; R69C, Mtm1 p.R69C; VEH, vehicle.
Lawlor et althis study identiﬁes several potentially useful therapeutic bio-
markers for this strategy and highlights the importance of
evaluating multiple muscles and myoﬁber types when assess-
ing treatment efﬁcacy, especially when whole-animal effects
are not apparent.1838A comparison of our two trials that used ActRIIB-mFc in
myotubularin-deﬁcient mice highlights several key differences
between treatment responses in Mtm1d4 and Mtm1 p.R69C
mice. Mtm1d4 and Mtm1 p.R69C show considerable differ-
ences in phenotypic severity, which is thought to be due to theajp.amjpathol.org - The American Journal of Pathology
Figure 7 ERK pathway activation in VEH- and
ActRIIB-treated mice. A: Western blot analysis shows
the relative expression of total ERK, p-ERK, total RSK/
P90, and p-RSK/P90 in the quadriceps and gastroc-
nemius muscles of (VEH- and ActRIIB-treated WT and
R69C mice at 6 MOL. GAPDH staining is used as a basis
for loading and quantiﬁcation studies. The numbers
under each set of two lanes refer to individual mice
from the study. B: Quantiﬁcation of the Western blot
results shown in A. Expression is normalized to the
GAPDH expression for each lane. These values were
obtained from gels in which the WT and R69C samples
were run in parallel on the same gels and immuno-
blotted on the same membranes. Data are expressed as
means  SEM. *P < 0.05. ActRIIB, ActRIIB-mFC; G,
gastrocnemius; Q, quadriceps; R69C, Mtm1 p.R69C;
VEH, vehicle.
ActRIIB Inhibition in Mtm1 p.R69C Micetotal absence of myotubularin inMtm1d4 mice in comparison
with a small amount of functional mutant myotubularin in
Mtm1 p.R69C mice.13 In Mtm1d4 mice, ActRIIB-mFc treat-
ment produced signiﬁcant increases in total body mass, which
corresponded to increases in the mass of all major muscles
measured (quadriceps, gastrocnemius, and triceps).12 Histo-
logically, this corresponded to marked hypertrophy of a subset
of ﬁbers, and this hypertrophy was restricted to a large sub-
population of the glycolytic (type 2b) myoﬁber population. In
the present trial, these patterns of hypertrophy (including
increased muscle size and hypertrophy restricted to the type 2b
ﬁber population) were virtually identical in the gastrocnemiusThe American Journal of Pathology - ajp.amjpathol.orgmuscles of Mtm1 p.R69C mice but were absent in the other
major muscles evaluated histologically (quadriceps and tri-
ceps). Because no apparent morphological differences were
found between the gastrocnemius, quadriceps, and triceps
muscles in untreated animals, we deduced that some factor
must affect treatment efﬁcacy that could vary between indi-
vidual muscles of the same animal. We chose to evaluate sat-
ellite cell expression and hypertrophic signaling in the
quadriceps and gastrocnemiusmuscles becausewewould least
expect variation between individual muscles of the hind limb.
The restriction of treatment responsiveness to type 2b
myoﬁbers in our prior study that usedMtm1d4mice suggested1839
Lawlor et althat the Akt pathway may be involved in the effectiveness of
ActRIIB-mFc in myotubularin-deﬁcient mice, so we evalu-
ated the activation of this pathway in the context of our
present results. Recent studies have shown that siRNA-
mediated silencing of myotubularin results in inhibition of
Akt phosphorylation in HeLa cells and primary human
skeletal muscle myotubes.22 By contrast, Akt and phospho-
Akt levels are reported to be both increased (such that the
phospho-Akt/Akt ratio is unaffected) in myotubularin-
deﬁcient mice.23 In our study, the levels of p-Akt were
similar in WT mice compared with Mtm1 p.R69C mice
(Figure 6), and evaluations of tissue from 6-week-old
Mtm1d4mice and theirWT littermates also showed similar or
increased levels of p-Akt in Mtm1d4 muscle (Supplemental
Figure S1). These data indicate that the ability to p-Akt is
intact in these two myotubularin-deﬁcient mouse models.
Although we were able to document the activation of
elements of the Akt pathway in treatment-responsive mus-
cles, it was surprising that the pattern of activation was
different in WT mice compared with Mtm1 p.R69C mice.
Treated WT mice, but not their Mtm1 p.R69C littermates,
displayed signiﬁcant increases in total Akt, p-Akt at Thr308,
and total P70/S6K in response to treatment with ActRIIB-
mFc. Prior work with myostatin inhibition to promote
myoﬁber hypertrophy has reported the involvement of the
Akt pathway in myoﬁber hypertrophy induced by myostatin
inhibition in myotubes24 and various mouse models.25e27
However, because the response to ActRIIB/myostatin inhi-
bition is not affected in Akt-deﬁcient mice,28 Akt itself is
not an absolute requirement for hypertrophy in this setting.
The key abnormalities of hypertrophic signaling found in
Mtm1 p.R69C mice were low levels of p-rpS6 and high
levels of p-eEF2K in the treatment-responsive gastrocne-
mius muscle in comparison with the treatment-resistant
quadriceps muscle (Figure 6). The amount of p-rpS6 in
the Mtm1 p.R69C gastrocnemius muscle is also lower than
that seen in age-matched WT muscles and muscles collected
from Mtm1d4 and WT mice at 6 WOL (Supplemental
Figure S1). Evidence suggests that activation of S6K
through the Akt pathway activates two opposing systems
related to global protein synthesis (reviewed in Meyuhas17).
Phosphorylation of EF2K and/or eukaryotic initiation factor
4B (eIF4B) produce increases in global protein synthesis,
whereas phosphorylation of rpS6 produces a decrease in
global protein phosphorylation,29 and together these mole-
cules are thought to ﬁne-tune protein synthesis after Akt
pathway activation. The relationship of rpS6 phosphoryla-
tion and cell size has primarily been elucidated in the
context of the lack of rpS6 phosphorylation, whereby the
inability to phosphorylate rpS6 has been associated with
decreased cell size (in a variety of cell types, including
muscle) and decreased muscle strength.30 For treatment
responsiveness in Mtm1 p.R69C mice, we did not identify
signaling abnormalities that explained the limitation of
treatment efﬁcacy in most muscles, but it is possible that the
low levels of p-rpS6 and the capacity to increase p-rpS61840with ActRIIB-mFc therapy would explain why the treatment
was more effective in the gastrocnemius muscle. The re-
lationships between eIF4B and EF2 and treatment efﬁcacy
in our study are unclear. eIF4B was not detectable with the
use of Western blot assays and p-EF2, whereas showing
higher levels in the Mtm1 p.R69C gastrocnemius muscle
than the quadriceps muscle (Figure 6) was not seen at higher
levels in treated animals.
Although we found that muscles that experienced hy-
pertrophy in response to ActRIIB-mFc treatment had higher
satellite cell numbers than were seen in vehicle-treated
muscles, the relationships among myostatin inhibition, sat-
ellite cell number, and hypertrophy remain unclear. Several
recent studies have established that satellite cells are not
necessary for hypertrophy in the context of myostatin in-
hibition,31,32 although other studies have implicated satellite
cell proliferation as an element of hypertrophy after myo-
statin inhibition.33 There is, however, more agreement with
the idea that myostatin can affect satellite cell biology, and
myostatin inhibition has been shown to increase satellite cell
proliferation in the context of dexamethasone treatment,34
muscle regeneration in diabetic mice,35 and satellite cell
number in chronic kidney disease.36 In the context of our
present ﬁndings, we observed a relationship between treat-
ment responsiveness and satellite cell number, but whether
the satellite cells directly contributed to the hypertrophic
response is less clear. Given that the treatment window here
extended from 2 WOL (when approximately 10% of ﬁbers
are associated with satellite cells) to 6 MOL (when the
number of ﬁbers associated with satellite cells has generally
decreased to approximately 5%), it is not clear whether
ActRIIB-mFc treatment produced satellite cell proliferation
or prevented the decrease in satellite cell numbers that
is normally observed with maturation. Signiﬁcantly, we
observed a similar depletion of satellite cells inMtm1 p.R69C
muscles andMtm1d4 muscle,8 and this depletion occurred to
an equivalent extent when comparing the vehicle-treated
Mtm1 p.R69C quadriceps and gastrocnemius muscles at 6
MOL. These data suggest that the differential efﬁcacy of
ActRIIB-mFc treatment was not a consequence of satellite
cell number differences between these muscles in the non-
treated state. However, the data do suggest that the micro-
environmental factors that are permissive or restrictive of
hypertrophy in theMtm1 p.R69C quadriceps muscle can also
exert effects on satellite cell proliferation. As such, quanti-
ﬁcation of Pax7þ satellite cells may be a useful biomarker of
treatment efﬁcacy or processes interfering with treatment
efﬁcacy in future studies that involve myostatin inhibition.
Overall, this study establishes that the treatment respon-
siveness of myotubularin-deﬁcient mice cannot be predicted
on the basis of symptomatic severity and that the response to
ActRIIB-mFc treatment varies considerably between indi-
vidual muscles from Mtm1 p.R69C mice. Our ﬁndings
indicate that ActRIIB-mFc has limited usefulness as a sole
therapeutic agent in the treatment of myotubularin deﬁ-
ciency, although it may be useful in combination with gene3ajp.amjpathol.org - The American Journal of Pathology
ActRIIB Inhibition in Mtm1 p.R69C Miceand enzyme replacement37 therapies for XLMTM that are
currently under development. The muscle-speciﬁc pattern of
hypertrophy observed here also provides a cautionary lesson
about the evaluation of treatment efﬁcacy at the whole-animal
level. Clearly, the commonly accepted hypertrophic pathways
are more complex than currently appreciated, because the
interactions between level of myotubularin deﬁciency, mus-
cle type, and ﬁber type lead to unpredictable outcomes.
Although the mechanism(s) responsible for the limitation of
treatment efﬁcacy inMtm1 p.R69C mice remain unclear, the
associations described here among myoﬁber hypertrophy,
p-rpS6, p-eEF2K, and satellite cell numbers provide useful
biomarkers for the evaluation of treatment efﬁcacy in myo-
tubularin deﬁciency or when inhibiting myostatin/ActRIIB
signaling in other disease states.
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